ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Simple Search Results

Didn't find what you were looking for? Try the Advanced Search »

  • « Previous Page
  • 1
  • …
  • 71
  • 72
  • 73
  • 74
  • 75
  • …
  • 96
  • Next Page »
Search Again »
  • Abstract Number: 0661 • ACR Convergence 2020

    Genomic Regions Jointly Associated with eGFR and Serum Urate: Implications for Shared Genetic Etiology of Hyperuricemia and Chronic Kidney Disease

    Nick Sumpter1, Alexa Lupi2, Megan Leask3, Tony Merriman4, Ana Vazquez2 and Richard Reynolds1, 1University of Alabama at Birmingham, Birmingham, AL, 2Michigan State University, East Lansing, MI, 3University of Otago, Dunedin, Otago, New Zealand, 4University of Otago, Dunedin, New Zealand

    Background/Purpose: Gout and hyperuricemia (HU), serum urate (SU) > 6.8 mg/dL, often present in the context of chronic kidney disease. It has long been known…
  • Abstract Number: 0664 • ACR Convergence 2020

    Uric Acid Level Is Associated with Severity of Heart Failure with Preserved Ejection Fraction

    Ana B. Arevalo1, Alba Munoz2, Faris Haddadin2, Karan Sud2, Gustavo Contreras2, Shane Murray2, Yousaf Ali2 and Edgar Argulian2, 1Mount Sinai St. Luke's-West/ Icahn School of Medicine, New York, NY, 2Mount Sinai St. Luke's-West/ Icahn School of Medicine, New York

    Background/Purpose: Hyperuricemia (HUC) has been shown to have an impact in the left atrium and left ventricle remodeling leading to the development of heart failure…
  • Abstract Number: 0665 • ACR Convergence 2020

    Trends in Immunomodulation/pegloticase Co-therapy from 2015-2019: A Claims Database Study

    Brian LaMoreaux1, John Botson2, Megan Francis-Sedlak1, Karl Svensson1 and Robert Holt1, 1Horizon Therapeutics plc, Lake Forest, IL, 2Orthopedic Physicians Alaska, Anchorage, AK

    Background/Purpose: Pegloticase, a recombinant, PEGylated uricase enzyme, is used to treat uncontrolled gout in patients who do not improve on or are intolerant of oral…
  • Abstract Number: 0668 • ACR Convergence 2020

    Outcomes and Resource Utilization After Total Knee Arthroplasty in Calcium Pyrophosphate Crystal Deposition Disease Patients: Insights from the National Inpatient Sample Database

    Konstantinos Parperis1, Mohanad Hadi2 and Bikash Bhattarai3, 1University of Arizona College of Medicine Phoenix and University of Cyprus Medical School, Phoenix, 2Creighton University - Maricopa Medical Center/ Valleywise Health Medical Center, Phoenix, AZ, 3Valleywise Health, University of Arizona College of Medicine, Phoenix, AZ

    Background/Purpose: Total knee arthroplasty (TKA) is one of the most frequently performed orthopedic procedures in patients with joint cartilage destruction. Calcium pyrophosphate crystal deposition (CPPD)…
  • Abstract Number: 0674 • ACR Convergence 2020

    Disease Control of Hyperuricemia Newly Detected by Medical Check-up: A Retrospective Cohort Study of Health Insurance Claims Data in Japan

    Ruriko Koto1, Akihiro Nakajima1, Hideki Horiuchi1 and Hisashi Yamanaka2, 1Teijin Pharma Limited, Tokyo, Japan, 2Sanno Medical Center, Tokyo, Japan

    Background/Purpose: Japanese guidelines for managing gout and hyperuricemia recommend the initiation of urate-lowering therapy (ULT) to prevent gouty arthritis in subjects having asymptomatic hyperuricemia with…
  • Abstract Number: 0675 • ACR Convergence 2020

    AR882, a Potent and Selective Uricosuric Agent, Significantly Reduced Serum Urate Levels Following Multiple Ascending Once-Daily Doses in Healthy Subject Volunteers

    Zancong Shen1, Elizabeth Polvent2, Vijay Hingorani2, Andrea Clouser-Roche2, Chris Mikelatis2, Rongzi Yan2, Shunqi Yan2 and Li-Tain Yeh2, 1Arthrosi therapeutics, Laguna Hills, CA, 2Arthrosi Therapeutics Inc, Laguna Hills, CA

    Background/Purpose: AR882 is a potent and selective uric acid transporter 1 (URAT1) inhibitor under development for the treatment of hyperuricemia or gout. AR882 exhibited linear…
  • Abstract Number: 0686 • ACR Convergence 2020

    Renal Evolution During the First Year of Urate-lowering Therapy According to Sonographic Joint Deposition: Data from the Lille-Alicante Inception Cohort

    Irene Calabuig1, Anne Marty-Ané2, Laurène Norberciak3, Jean--Francois Budzik4, Agustín Martínez-Sanchis5, Mariano Andrés1 and Tristan Pascart3, 1Hospital General Universitario de Alicante-ISABIAL and Universidad Miguel Hernández de Elche, Alicante, Spain, 2GHICL, Lille, France, 3GHICL, Lomme, France, 4University of Lille, Lille, France, 5Hospital General Universitario de Alicante-ISABIAL, Alicante, Spain

    Background/Purpose: Gout is associated with chronic kidney disease, but how the kidney function evolves when gout is treated with urate lowering therapy (ULT) is still…
  • Abstract Number: 0951 • ACR Convergence 2020

    The Comparative Effect of Exposure to Various Risk Factors on the Risk of Hyperuricaemia: Diet Has a Weak Causal Effect

    Ruth Topless1, Tanya Major1, Jose Florez2, Joel Hirschhorn3, Murray Cadzow1, Nicola Dalbeth4, Lisa Stamp5, Phillip Wilcox1, Richard Reynolds6, Joanne Cole2 and Tony Merriman1, 1University of Otago, Dunedin, New Zealand, 2Massachusetts General Hospital, Boston, 3Harvard Medical School, Boston, 4University of Auckland, Auckland, New Zealand, 5University of Otago Christchurch, Christchurch, New Zealand, 6University of Alabama Birmingham, Birmingham

    Background/Purpose: Prevention of hyperuricaemia (HU) is critical to the prevention of gout. Therefore, understanding the causal relationships and relative contributions of various risk factors to…
  • Abstract Number: 1164 • ACR Convergence 2020

    Frequency of Genetic Diagnosis in an Autoinflammatory Disease Natural History Protocol Cohort of Patients

    Katelin R. Honer1, Kim Johnson1, Gema Souto Adeva1, Gina Montealegre Sanchez2, Jenna Wade3, Jacob Mitchell1, Katherine Townsend3, Adriana de Jesus4 and Raphaela Goldbach-Mansky5, 1Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Bethesda, MD, 2Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Rockville, MD, 3Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Bethesda, 4Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Silver Spring, MD, 5Translational Autoinflammatory Disease Section (TADS)/NIAID/NIH, Potomac, MD

    Background/Purpose: Monogenic autoinflammatory diseases (AID) are caused by innate immune dysregulation resulting in systemic inflammation and variable organ-specific clinical manifestations. The Translational Autoinflammatory Disease Section…
  • Abstract Number: 1316 • ACR Convergence 2020

    Patient Perceptions of Fibromyalgia Symptoms and the Overlap with Axial Spondyloarthritis

    Kelly Gavigan1, William Nowell2, Regan Reynolds1, Laura Stradford1, Jeffrey R Curtis3 and Alexis Ogdie4, 1Global Healthy Living Foundation, Upper Nyack, NY, 2Global Healthy Living Foundation, New York City, NY, 3Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 4University of Pennsylvania, Philadelphia, PA

    Background/Purpose: In clinical practice, it is often challenging to distinguish fibromyalgia syndrome (FMS) from axial spondyloarthritis (axSpA), which includes ankylosing spondylitis and non-radiographic axSpA. Early stages…
  • Abstract Number: 1472 • ACR Convergence 2020

    Assessing Causal Associations of Urate Levels with Type 2 Diabetes and Related Glycemic Traits Using Bidirectional Mendelian Randomization

    Natalie McCormick1, Mark O'Connor1, Shelby Marozoff2, John Choi3, Aaron Leong1 and Hyon Choi4, 1Massachusetts General Hospital, Boston, MA, 2Arthritis Research Canada, Vancouver, Canada, 3Massachusetts General Hospital, Boston, 4Massachusetts General Hospital, Department of Medicine, Division of Rheumatology, Lexington, MA

    Background/Purpose: Type 2 diabetes (T2D) and gout/hyperuricemia frequently coexist, but the nature and direction of this relationship is unclear.  Observational studies have reported positive associations…
  • Abstract Number: 1550 • ACR Convergence 2020

    Change in Tophus Size Measured with Dual-energy CT and Ultrasound: A 1-year Multicenter Follow-up Study

    Tristan Pascart1, Pascal Richette2, Sebastien Ottaviani3, Laurène Norberciak1, Hang Korng EA4, Frédéric Lioté5, Jérémy Ora6, Julie Legrand1, Valérie Bousson6, Elyas Mahdjoub7 and Jean--Francois Budzik8, 1GHICL, Lomme, France, 2Department of Rheumatology, Lariboisière Hospital, Paris, France, 3Rheumatology Department, Bichat hospital, APHP, Paris, France, 4Universite de Paris, AP-HP, INSERM, paris, France, 5AP-HP, Paris, France, 6Lariboisière Hospital, Paris, France, 7Bichat Hospital, Paris, France, 8University of Lille, Lille, France

    Background/Purpose: Dual-Energy computed tomography (DECT) and ultrasound are the two techniques able to identify and measure monosodium urate (MSU) crystal deposition, and both are considered…
  • Abstract Number: 1577 • ACR Convergence 2020

    Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis Impact on Function and Patient-Reported Quality of Life Measures Varies Depending on Pattern of Arthritis

    Jeffrey Sarazin1, Ann Impens2, Nada Abdulaziz1, Stacey Anderson3, Leslie Fecher1, Christopher Lao1 and Elena Schiopu1, 1Michigan Medicine, Ann Arbor, MI, 2Midwestern University, Ann Arbor, IL, 3University of Michigan, Ann Arbor, MI

    Background/Purpose: Immune checkpoint inhibitors (ICIs) have emerged as a paradigm shift in the treatment of malignancies, but can have significant side effects, termed immune related…
  • Abstract Number: 1648 • ACR Convergence 2020

    Comparison of Methotrexate and Glucosamine in Primary Knee Osteoarthritis with Inflammation

    Biswadip Ghosh1, Subhankar Haldar2 and Meghna Saha2, 1IPGME&R, Kolkata, Kolkata, West Bengal, India, 2IPGME&R, Kolkata, KOLKATA, India

    Background/Purpose: Many patients suffering from knee OA show swelling, warmth along with pain which are features of inflammation. There are no accepted pharmacological therapy for osteoarthritis…
  • Abstract Number: 1723 • ACR Convergence 2020

    RA Flare Prediction via Machine Learning and Algorithm Based on SSDM Big Data

    Yan Zhao1, Rong Mu2, Xiaomei Li3, Hongsheng Sun4, Cundong Mi5, Guosheng Wang3, Shengqian Xu6, Minghua Xu7, Haiying Chen8, Qingchun Huang9, Ling Lei10, HaiLi Shen11, Hui Xiao12, Yuhua Jia13, Bing Wu13, Xin Chen12, Shengsong Jia12 and Fei Xiao13, 1Peking Union Medical College hospital, Beijing, Beijing, China (People's Republic), 2People's Hospital, Beijing University Medical School, Beijing, Beijing, China (People's Republic), 3the First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui, China (People's Republic), 4Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, China (People's Republic), 5The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China (People's Republic), 6the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China (People's Republic), 7Affiliated Hospital of Hebei University, Baoding, Hebei, China (People's Republic), 8The Third Affiliated Hospital of Hebei Medical University, Shijiazhuang, Hebei, China (People's Republic), 9Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, Guangdong, China (People's Republic), 10The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China (People's Republic), 11Second Hospital of Lanzhou University, Lanzhou, Gansu, China (People's Republic), 12Shanghai Gothic Internet Technology Co., Ltd., Shanghai, Shanghai, China (People's Republic), 13Shanghai Gothic Internet Technology Co., Ltd., Shanghai, China (People's Republic)

    Background/Purpose: Flare, relapse from status of treat-to-target (T2T, DAS28< =3.2), is hard predicted. We try to make it predictable by applying machine learning to a…
  • « Previous Page
  • 1
  • …
  • 71
  • 72
  • 73
  • 74
  • 75
  • …
  • 96
  • Next Page »
Search Again »

Didn't find what you were looking for? Try the Advanced Search »

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology